To assess the long-term cost-effectiveness of various doses of rosuvastatin (R) versus relevant doses of simvastatin (S) (R20 mg versus S40 mg (primary analysis), R10 versus S20 and R10 versus S40) in a patient population with high risk of cardiovascular events (10-year Framingham CVD risk ≥ 20%). METHODS: A Monte Carlo simulation model was developed based on the JUPITER (Justifi cation for the Use of statins in Primary prevention: an Intervention Trial evaluating Rosuvastatin, NCT00239681) trial fi ndings and includes modeling of cardiovascular events and death over the lifetime of patients. The relative effi cacy of S20, S40 and R10 compared with R20 (as observed in JUPITER) was estimated by computing relative 10-year Framingham cardiovascular event risks based on reported differences in Total Cholesterol/High-Density Lipoprotein cholesterol ratio. Epidemiological data specifi c for the Swedish setting were utilized to model post-event mortality and long-term overall mortality in event-free patients. Incremental effectiveness was primarily measured as quality-adjusted life-years (QALYs) gained. Cost-effectiveness was assessed based upon direct costs. All effects and costs (in 2008/09 Swedish unit prices) were discounted at annual 3%. RESULTS: The model estimated that treating a cohort of 100,000 patients (66 years, 60% males) with R20 mg avoided 2642 CVD events over lifetime compared with S40 mg. This translated into an estimated gain of 9515 years in full health (QALYs). The incremental cost per QALY gained was SEK161,712 (16,434). The cost per QALY gained was SEK228,655 (c23,237) for R10 versus S20, and SEK234,932 (c23,875) for R10 versus S40. Probabilistic sensitivity analyses supported base-case results. CONCLUSIONS: Treatment with rosuvastatin 10 and 20 mg is cost-effective compared with relevant doses of simvastatin in the primary prevention of CVD for patients with high baseline cardiovascular risk (10-year Framingham CVD risk ≥ 20%). To assess long-term cost-effectiveness of various doses of rosuvastatin (R) versus relevant doses of generic atorvastatin (A) (R20 mg versus A40 mg (primary comparison), R10 versus A20 and; R40 versus A80) in patients with a high risk of CV events (10-year Framingham CVD risk ≥ 20%). METHODS: A Monte Carlo simulation model was developed based on JUPITER (Justifi cation for the Use of statins in Primary prevention: an Intervention Trial evaluating Rosuvastatin, NCT00239681) trial fi ndings and modeled cardiovascular events and death over the lifetime of patients. The relative effi cacy of the A20, A40, A80, R10, and R40 mg compared to R20 mg (as observed in JUPITER) were estimated by computing relative 10-year Framingham cardiovascular event risks based on reported differences in Total Cholesterol/High-Density Lipoprotein cholesterol ratio. Epidemiological data specifi c for the Swedish setting were utilized to model mortality. Incremental effectiveness was primarily measured as quality-adjusted life-years (QALYs) gained. Cost-effectiveness was assessed based upon direct costs. All effects and costs (2008/09 Swedish unit prices) were discounted at annual 3%. An 80% price reduction was assumed for generic versus branded statin. RESULTS: The model estimated that treating a cohort of 100,000 patients (66 years, 60% males) with R20 avoided 1121 CVD events over lifetime compared with atorvastatin 40 mg. This translated into an estimated gain of 4090 years in full health (QALYs). The estimated incremental cost per QALY gained was SEK366,763 (c37,273). This estimate was SEK428,060 (c43,502) for R10 versus A20, and SEK582,241 (c59,171) for R40 versus A80. Probabilistic sensitivity analyses supported base-case results. CONCLUSIONS: Treatment with rosuvastatin 10 mg, 20 mg and 40 mg is cost-effective compared with relevant doses of generic atorvastatin (20 mg, 40 mg, 80 mg, respectively) for the primary prevention of cardiovascular events for patients with high baseline cardiovascular risk (10-year Framingham CVD risk ≥ 20%) in Sweden.
PCV91 THE COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS ATORVASTATIN FOR THE PREVENTION OF CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS WITH HIGH BASELINE RISK-A SWEDISH ECONOMIC EVALUATION OF THE JUPITER TRIAL
Olsson AG 1 , Jensen MM 2 , Gandhi SK 3 , Fox KM 4 , Paulsson T 5 1 Linköping University Sweden, Linköping, Sweden; 2 AstraZeneca, Lund, Sweden; 3 AstraZeneca LP, Wilmington, DE, USA; 4 University of Maryland School of Medicine, Monkton, MD, USA; 5 AstraZeneca Nordic MC, Södertälje, Sweden OBJECTIVES: To assess long-term cost-effectiveness of various doses of rosuvastatin (R) versus relevant doses of generic atorvastatin (A) (R20 mg versus A40 mg (primary comparison), R10 versus A20 and; R40 versus A80) in patients with a high risk of CV events (10-year Framingham CVD risk ≥ 20%). METHODS: A Monte Carlo simulation model was developed based on JUPITER (Justifi cation for the Use of statins in Primary prevention: an Intervention Trial evaluating Rosuvastatin, NCT00239681) trial fi ndings and modeled cardiovascular events and death over the lifetime of patients. The relative effi cacy of the A20, A40, A80, R10, and R40 mg compared to R20 mg (as observed in JUPITER) were estimated by computing relative 10-year Framingham cardiovascular event risks based on reported differences in Total Cholesterol/High-Density Lipoprotein cholesterol ratio. Epidemiological data specifi c for the Swedish setting were utilized to model mortality. Incremental effectiveness was primarily measured as quality-adjusted life-years (QALYs) gained. Cost-effectiveness was assessed based upon direct costs. All effects and costs (2008/09 Swedish unit prices) were discounted at annual 3%. An 80% price reduction was assumed for generic versus branded statin. RESULTS: The model estimated that treating a cohort of 100,000 patients (66 years, 60% males) with R20 avoided 1121 CVD events over lifetime compared with atorvastatin 40 mg. This translated into an estimated gain of 4090 years in full health (QALYs). The estimated incremental cost per QALY gained was SEK366, 763 (c37, 273) . This estimate was SEK428,060 (c43,502) for R10 versus A20, and SEK582,241 (c59,171) for R40 versus A80. Probabilistic sensitivity analyses supported base-case results. CONCLUSIONS: Treatment with rosuvastatin 10 mg, 20 mg and 40 mg is cost-effective compared with relevant doses of generic atorvastatin (20 mg, 40 mg, 80 mg, respectively) for the primary prevention of cardiovascular events for patients with high baseline cardiovascular risk (10-year Framingham CVD risk ≥ 20%) in Sweden.
PCV92 THE HEALTH AND ECONOMIC IMPACT OF SWITCHING FROM ATORVASTATIN TO GENERIC SIMVASTATIN IN BELGIUM
The University of Melbourne, Fitzroy, Victoria, Australia; 2 Pfi zer Limited, Surrey, UK; 3 Pfi zer, Bruxelles, Belgium OBJECTIVES: Containing pharmaceutical budgets has encouraged generic prescribing policies. Across Europe, many patients have been switched from atorvastatin to generic statins, particularly simvastatin, but often at lower therapeutic doses. This study sought to estimate the potential clinical and economic effect if policy-induced switching to fi rst generation statins occurred in Belgium as per previously observed patterns. METHODS: A Markov micro-simulation model was populated with 80 primary prevention Belgian patients from a 2007 observational study. Risks of fi rstonset cardiovascular disease (CVD) were estimated using a calibrated Framingham risk equation. With a baseline of January 2010, follow-up was simulated for 20 years. Decision analysis estimated the marginal effects of switching all patients from atorvastatin (weighted average daily dose [WADD] 20.7 mg) to simvastatin (WADD 31.6 mg). Dose-specifi c, lipid-modifying effects of the two statins, CVD costs and utilities were sourced from published data. Annual discount rates of 3% and 1.5% were applied to costs and health effects, respectively. RESULTS: Of the 80 subjects on atorvastatin, 23 (28.9%) were predicted to develop CVD over 20 years. In the switched-to-simvastatin group, the predicted number was 26 (32.0%), equating to a "number needed to harm" of 32. Switching was estimated to lead to a net cost saving of c581 per subject, but also a loss of 0.04 QALYs. These equated to an ICER of c13,608 per QALY gained (atorvastatin vs. simvastatin). Sensitivity analyses indicated the results to be robust. CONCLUSIONS: Our preliminary analyses indicate that there would be an increase in the burden of CVD if Belgian patients are switched from atorvastatin to generic simvastatin at non-equipotent doses, as has happened in neighbouring countries like The Netherlands. This study highlights the need to consider the potential health and health economic impact of population-based switching policies.
PCV93 THROMBOPROPHYLAXIS AFTER TOTAL KNEE REPLACEMENT: COST-UTILITY ANALYSIS OF RIVAROXABAN VERSUS ENOXAPARIN IN
Slovak Medical University, Bratislava, Slovak Republic; 2 Trencin University, Trencin, Slovak Republic; 3 Bayer, Uxbridge, UK; 4 Slovak Society for Pharmacoeconomics, Bratislava, Slovak Republic; 5 Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic OBJECTIVES: To estimate the cost-effectiveness of rivaroxaban against enoxaparin for the prophylaxis of venous thromboembolism (VTE) in patients after total knee replacement (TKR) in Slovakia from payer perspective. METHODS: Previously published cost-utility model based on results of large randomized controlled trial (RECORD 3) has been adapted to Slovakian settings. In RECORD 3, patients received 12 days prophylaxis with rivaroxaban or enoxaparin. Rivaroxaban reduced total VTE (composite: any DVT, non-fatal PE, all-cause mortality) by 49% versus enoxaparin after 12 days prophylaxis. The model was divided into three parts: prophylaxis, postprophylaxis, and long-term complications. The fi rst two parts represents acute phase and were modeled as a decision tree. Third part represents the long-term complications and was developed as a Markov model. The fi rst part of the model is populated by RECORD 3 trial, while published epidemiological and clinical data estimating the risk of further VTE events and post-thrombotic syndrome beyond the trial period were used in second and third part of the model. Local cost data was based on published price lists, clinical guidelines, product labels and expert opinion. VTE related utilities were used from literature. Effectiveness was measured in quality-adjusted life-years (QALY). Time horizon was set at 5 years and payers perspective was used. Discount rate was 5% per year for costs and effects according to valid Ministry of Health (MoH) guidelines for health economic evaluation. One-way and probabilistic sensitivity analyses were performed. RESULTS: Rivaroxaban produced improved outcomes (QALY) and cost savings of c28 per patient versus enoxaparin in Slovakian setting (dominance). Probabilistic sensitivity analysis showed dominance of rivaroxaban compared to enoxaparin in more then 99% of cases. CONCLUSIONS: Prophylaxis of VTE with rivaroxaban following TKR may improve health outcomes and reduce direct medical costs when compared to enoxaparin in Slovakian setting.
